GSK, CureVac’s COVID-19 vaccine candidate shows promise in preclinical study

A preclinical study investigating CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, compared to its GlaxoSmithKline-partnered second-generation vaccine candidate, CV2CoV, has found that better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies and stronger memory B and T cell activation, as compared to CVnCoV.